Safety Evaluation of Initial CT-P6 Administration for 30 min during the Switch from Reference Trastuzumab in Maintenance Infusion: A Multicenter Observational Study-Reference-Cited by-同舟云学术

Safety Evaluation of Initial CT-P6 Administration for 30 min during the Switch from Reference Trastuzumab in Maintenance Infusion: A Multicenter Observational Study

Published:2021-04-01 Issue:4 Volume:44 Page:474-477
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Saito Yoshitaka¹,Tamaki Shinya²,Hasegawa Haruka³,Takahashi Kenta⁴,Tokutome Akira⁵,Takekuma Yoh¹,Yamashita Hiroko⁶,Komatsu Yoshito⁷,Sugawara Mitsuru¹⁸

Affiliation:

1. Department of Pharmacy, Hokkaido University Hospital

2. KKR Sapporo Medical Center

3. Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center

4. Department of Pharmacy, NTT Medical Center Sapporo

5. Department of Pharmacy, Sapporo Higashi Tokushukai General Hospital

6. Department of Breast Surgery, Hokkaido University Hospital

7. Cancer Center, Hokkaido University Hospital

8. Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/44/4/44_b20-00984/_pdf

Reference21 articles.

1. 1) Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N. Engl. J. Med., 357, 39–51 (2007).

2. 2) Lee J, Kang HA, Bae JS, Kim KD, Lee KH, Lim KJ, Choo MJ, Chang SJ. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses. MAbs, 10, 547–571 (2018).

3. 3) Slamon DJ, Godolphin W, Jones LA, Holt J, Wong S, Keith D, Levin W, Stuart S, Udove J, Ullrich A, et. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707–712 (1989).

4. 4) Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol., 19, 1523–1529 (2008).

5. 5) Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist, 14, 320–368 (2009).

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infusion Reactions in HER2-Positive Gastric Cancer: Switching from Trastuzumab to Its Biosimilar;Biological and Pharmaceutical Bulletin;2024-08-21

2. Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States;Expert Opinion on Biological Therapy;2023-03-09

3. Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer;Biomedicines;2022-08-21

4. Trastuzumab;Reactions Weekly;2021-06